Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma

Ernst-Stecken, Antje; Ganslandt, Oliver; Lambrecht, Ulrike; Sauer, Rolf; Grabenbauer, Gerhard G.

doi:10.1007/s11060-006-9231-0

Cited by 83 publications

(53 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the last decade, there has been an increased interest in fractionated stereotactic reirradiation as a palliative measure for patients with recurrent GBM, in combination with chemotherapy and reresection, if possible [9,16,21,22]. In this study, we found a median OS of 27 months estimated from the first diagnosis.…”

Section: Resultsmentioning

confidence: 53%

Hypofractionated Stereotactic Reirradiation of Recurrent Glioblastomas

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 53%

Hypofractionated Stereotactic Reirradiation of Recurrent Glioblastomas

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The effect of reirradiation, specifically on HRQOL, was evaluated in a small study with a median follow-up of 9 months [49]. The majority of patients (80%) judged their general health status after reirradiation to be stable or even improved, compared with before treatment; in 20% of patients, their perceived general health status declined.…”

Section: Effect Of Radiotherapy On Hrqolmentioning

confidence: 99%

Review on Quality of Life Issues in Patients with Primary Brain Tumors

2010

View full text Add to dashboard Cite

Health-related quality of life (HRQOL) has become an important outcome measure in clinical trials in primary brain tumor (i.e., glioma) patients, because they have an incurable disease. HRQOL is assessed using self-reported, validated questionnaires, addressing physical, psychological, emotional, and social issues. In addition to generic HRQOL instruments, disease-specific questionnaires have been developed, including for brain tumor patients. For the analysis and interpretation of HRQOL measurements, low compliance and missing data are methodological challenges. HRQOL in glioma patients may be negatively affected by the disease itself as well as by side effects of treatment. But treatment with surgery, radiotherapy, and chemotherapy may improve patient functioning and HRQOL, in addition to extending survival.Although HRQOL has prognostic significance in brain tumor patients, it is not superior to well-known clinical parameters, such as age and performance status. In clinical practice, assessing HRQOL may be helpful in the communication between doctor and patient and may facilitate treatment decisions. The Oncologist 2010;15:618 -626

show abstract

“…For recurrent high-grade glioma, radiochemotherapy may further increase the treatment efficiency. There are many studies delivering hypofractionated SRS with doses between 3 and 5 Gy per fraction for local relapse after prior conventional radiotherapy doses of 60 Gy [9,14,15,18]. The resulting overall survival after hypofractionated stereotactic re-irradiation ranges from 10 months for high-grade tumors to 20 months for low-grade lesions.…”

Section: Brain Gliomamentioning

confidence: 99%

Stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT) for neurooncological and neurological diseases: state of the art and future perspectives

Münter

Welker

Jensen

et al. 2013

Innovative Neurosurgery

View full text Add to dashboard Cite

Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (SRT) are well established in a high number of neurooncological and neurological lesions. Modern technologies discussed in this review, especially the integration of multimodality imaging in the daily clinical routine, will further improve the results of SRS and SRT. Currently, the different technical methods used are comparable regarding the clinical results in different clinical indications. The technological advances allow high treatment flexibility, and therefore, new treatment indications can be established based on the new technologies. In the future, it has to be defined more clearly whether a single fraction, hypofractionated concepts, or fractionated stereotactic radiotherapy is more effective regarding the clinical results and side effects of the therapy. The main area of development for radiosurgery will be stereotactic body radiosurgery. More randomized clinical studies for all possible indications are needed in the next few decades in order to establish radiosurgery more precisely, and also to determine its true value, especially in normal-fractionated radiotherapy. In technological development, the next step has been completed and proton or particle based stereotactic radiosurgery may have increased use in the future.

show abstract

Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma

Cited by 83 publications

References 34 publications

Hypofractionated Stereotactic Reirradiation of Recurrent Glioblastomas

Hypofractionated Stereotactic Reirradiation of Recurrent Glioblastomas

Review on Quality of Life Issues in Patients with Primary Brain Tumors

Stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT) for neurooncological and neurological diseases: state of the art and future perspectives

Contact Info

Product

Resources

About